

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : YOUNG et al.

INVENTION: : INDIVIDUALIZED ANTI-CANCER ANTIBODIES

SERIAL NUMBER APR 22 2002 : 09/727,370

FILING DATE : November 29, 2000

EXAMINER: : Helms, L.

GROUP ART UNIT : 1642 COPY OF PAPERS
ORIGINALLY FILED

ATTORNEY DOCKET NO. : 2056.007

RECEIVED

APR 25 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

MAY 17 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 4/12/02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

**This is not responsive to the Office Action mailed February 22, 2002. A response
will be filed in due course.**

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the
accompanying form PTO-1449 are hereby brought to the attention of the Examiner for
independent evaluation. A copy of each reference is enclosed.

These references were made of record in the parent application U.S. Serial No.
09/415,278 now U.S. Patent NO. 6,180,357, upon which the present application claims priority
under 35 U.S.C. §120. Pursuant to 37 C.F.R. §1.98(d). Applicants are not required to submit
copies of these references.

Also, U.S. Patent Nos. 5,869,045 and 4,939,240; EP 0 222 360 and WO 94/18345 were cited in the preliminary search report of the European Patent Office in the corresponding European patent application. Copies of these references are enclosed.

A copy of the European search report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Respectfully submitted,

Date: 4/12/2002

By: Ferris H. Lander
Ferris H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

E:\FILES\SH\2000-2100\2056.007 ids.wpd

X spe
6A47164

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : YOUNG et al.

INVENTION: INDIVIDUALIZED ANTI-CANCER ANTIBODIES

SERIAL NUMBER: 09/727,370

FILING DATE: November 29, 2000

EXAMINER: Helms, L.

GROUP ART UNIT: 1642

COPY OF PAPERS
ORIGINALLY FILED

ATTORNEY DOCKET NO.: 2056.007

RECEIVED
APR 25 2002

TECH CENTER 1600/2900

RECEIVED

MAY 17 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 4-12-02

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

Petition to Commissioner Pursuant to 37 CFR 1.97(d)
 Information Disclosure Statement
 PTO-1449
 References
 Please charge Deposit Account No. 13-0439 in the amount of \$180.00 for Petition fee.
 Please charge any deficiencies or credit any overpayment to Deposit Account No. 13-0439.
This Transmittal Letter is submitted in duplicate.

Respectfully submitted,

By: Ferris H. Lander
Ferris H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

Date: 4/12/2002

Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2056.007

APPLICATION NO.
09/727,370


INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
YOUNG et al.

FILING DATE
11/29/00

GROUP
1642



U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,750,102	05/98	Eisenbach et al.			
	4,861,581	08/89	Epstein et al			
	5,171,665	12/92	Hellstrom et al.			
	5,484,596	01/96	Hanna, Jr. et al.			
	5,693,363	12/97	Codington et al.			
	5,783,186	07/98	Arakawa et al.			
	5,849,876	12/98	Linsley et al.			
	5,869,045	02/99	Hellstrom et al.			
	5,869,268	03/99	Kudo et al			
	5,780,033	07/98	Torchillinn et. al.			
	4,172,124	10/79	Koprowski et al.			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Herlyn et al., Int. J. Cancer 27, (1981); pp.769-774
		Knuth et al., Proc. Am. Assoc. Cancer Res. 25; (1984) p.1005
		Cruse et al., Illustrated Dictionary of Immunology, CRC Press, (1995) p.280
		Horoszewicz et al., Anticancer Research 7, (1987) pp. 927-36.

EXAMINER DATE CONSIDERED

- EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

MAY 17 2002

RECEIVED

APR 25 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED



Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2056.007

APPLICATION NO.
09/727,370

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
YOUNG et al.

FILING DATE
11/29/00

GROUP
1642

RECEIVED

APR 25 2002

TECH CENTER 1600/2
TECH CENTER 1600/2900

MAY 17 2002

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Badger CC, Bernstein ID. "Prospects for monoclonal antibody therapy of leukemia and lymphoma". Cancer Vol. 58., (1986) pp.584-9.
			Begg AC, Mooren E; "Rapid fluorescence-based assay for radiosensitivity and chemosensitivity testing in mammalian cells in vitro". Cancer Research., Vol. 49, (1986) pp.565-9.
			Boven E, Pinedo HM.; "Monoclonal antibodies in cancer treatment: where do we stand after 10 years?" Radiotherapy & Oncology. Vol. 5, (1986) pp.109-17.
			Costa A, Silvestrini R, Del Bino G, Motta R.; "Implications of disaggregation procedures on biological representation of human solid tumours". Cell Tissue Kinet, Vol 20, (1987) pp.171-80.
			Dairkee SH, Paulo EC, Traquina P, Moore DH, Ljung BM, Smith HS; "Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells". Cancer Res. Vol. 57. (1997) pp.1590-6.
			Dillman RO, "Monoclonal antibodies for treating cancer". Annals of Internal Medicine. Vol. 111 (1989) pp.592-603.
			Dillman RO.; "Antibodies as cytotoxic therapy"; Journal of Clinical Oncology, Vol. 12, (1994) pp.1497-515.
			Disis ML, Cheever MA; "Her-2/neu protein: a target for antigen-specific immunotherapy of human cancer". Advances in Cancer Research, Vol. 71 (1997) pp.343-71.
			Dvorak HF, Nagy JA, Dvorak AM.; "Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies". Cancer Cells; Vo. 3. (1991) pp.77-85.
			Engelhohn SA, Spang-Thomsen M, Brunner N, Nohr I, Vindelov. LL.; "Disaggregation of human solid tumours by combined mechanical and enzymatic methods". Br J. Cancer. Vol 51. (1985) pp.93-8.
			Epsstein AL, Marder RJ, Winter JN, et al.; "Two new monoclonal antibodies; Lym-1 and Lyn02, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential". Cancer Research. Vol. 47 (1987) pp830-40.
			Foon KA.; "Biological therapy of cancer". Breast Cancer Research & Treatment. Vol. 7 (1986) pp.5-14.
			Franzen B, Linder S, Okuzawa K, Kato H, Auer G. "Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis". Electrophoresis. Vol. 14 (1993) pp.1045-53.
			Harris DT, Mastrangelo MJ.; "Serotherapy of cancer". Seminars in Oncology. Vol. 16 (1989) pp.180-98.
			Holz E, Raab R, Rietlunuller G.; "Antibody-based immunotherapeutic strategies in colorectal cancer". Recent Results in Cancer Research. Vol. 142 (1996) pp.381-400.
			Kravtsov VD, Fabian 1.; "Automated monitoring of apoptosis in suspension cell cultures". Laboratory Investigation. Vol. 74 (1996) pp.557-70.

EXAMINER

DATE CONSIDERED

- EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

APR 25 2002

TECH CENTER 1600/29

COPY OF PAPERS
ORIGINALLY FILED

**Form PTO-1449
(Rev. 2-88)**

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2056.007

APPLICATION NO.
09/727,370

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
YOUNG et al.

FILING DATE
11/29/00

GROUP
1642

U.S. PATENT DOCUMENTS

RECEIVED

MAY 17 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

- EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.